Tradename: MenQuadfi
Proper Name: Meningococcal (Groups A, C, Y, W) Conjugate Vaccine
Indication: To include safety and effectiveness data from clinical studies MET59 and MEQ66 in support of booster vaccination of individuals 13 years of age and older who are at continued risk for meningococcal disease if at least 3 years have elapsed since a prior dose of meningococcal (groups A, C, W, Y) conjugate vaccine, and vaccination following a prior dose of meningococcal polysaccharide vaccine if at least 3 years have elapsed since the prior dose of meningococcal polysaccharide vaccine.
MenQuadfi is a vaccine indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. MenQuadfi is approved for use in individuals 2 years of age and older.
MenQuadfi does not prevent N. meningitidis serogroup B disease.
Approval Date: 06/09/2023
Manufacturer: Sanofi Pasteur Inc.
More: https://www.fda.gov/vaccines-blood-biologics/menquadfi